Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label phase II study to evaluate the efficacy and safety of
Capecitabine plus oxaliplatin (XELOX) in the peri-operative treatment of patients with
potentially resectable liver metastasis from colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Guangdong General Hospital Guangdong Provincial People's Hospital